# US 2004/0082009 A1 · Compositions and methods for regulating receptor clustering

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082009 A1
- Document ID: US20040082009A1
- Status: Published application
- Kind: A1
- Application number: 10/250,935
- Filed: 2003-12-15
- Published: 2004-04-29
- Earliest claimed: 2003-12-15
- Assignees: Mount Sinai Hospital
- Inventors: Jim Dennis; Michael Demetriou
- Web page: https://patentgrep.com/patent/US20040082009A1

## CPC

- G01N 33/5091: {for testing the pathological state of an organism}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/4726: {Lectins}
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 2333/4724: Lectins
- G01N 2500/00: Screening for compounds of potential therapeutic value
- Y10T 436/143333: Saccharide [e.g., DNA, etc.]
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The invention relates to isolated complexes comprising one or more galectin associated with a Mgat5 modified glycan or polylactosamine modified glycan, and isolated lectin-Mgt5 modified glycan lattice comprising an array of mulitvalent interactions among lectins, Mgat5 modified glycans, polylactosamine modified glycans, and/or glycoproteins. Methods for evaluating a test compound for its ability to regulate receptor clustering through glycans on cell surfaces; and methods for regulating receptor clustering on cell surfaces comprising altering glycans on the cell surface associated with receptor clustering are also disclosed.

## Claims

### Claim 1

An isolated complex comprising one or more galectin interacting with a Mgat5 modified glycan or polylactosamine modified glycan that is associated with receptor clustering.

### Claim 2

An isolated lectin-Mgat5 modified glycan lattice comprising an array of multivalent interactions among lectins, Mgat5 modified glycans, polylactosamine modified glycans, and/or glycoproteins that are associated with receptor clustering.

### Claim 3 (depends on 2)

An isolated lectin-Mgat5 modified glycan lattice as claimed in claim 2 wherein the Mgt5 modified glycans and polylactosamine modified glycans are part of glycoproteins of receptors, preferably T cell receptors.

### Claim 4

A method for evaluating a test compound for its ability to regulate receptor clustering through glycans on cell surfaces comprising assaying for alterations of the glycans in the presence of the test compound.

### Claim 5

A method for evaluating a compound for its ability to regulate receptor clustering through a lectin-Mgat5 modified glycan lattice comprising (a) mixing a lectin-Mgat5 modified glycan lattice, or a lectin and one or more of a Mgat5 modified glycan and polylactosamine modified glycan, and a test compound, under conditions which maintain the lattice or permit the formation of complexes between the lectin and one or more of the Mgat5 modified glycan and polylactosamine modified glycan; and (b) removing and/or detecting lectin-Mgat5 modified glycan lattice, complexes, lectin, Mgat5 modified glycan, or polylactosamine modified glycan

### Claim 6 (depends on 5)

A method as claimed in claim 5 wherein the lectin-Mgat5 modified glycan lattice is a galectin-Mgat5 modified glycan lattice and the lectin is a galectin.

### Claim 7

A cell based assay for evaluating a test compound for its ability to regulate receptor clustering through a lectin-Mgat5 modified glycan lattice or component thereof comprising (a) providing cells with receptors whereby clustering of the receptors is regulated through a lectin-Mgat5 modified glycan lattice or one or more of a lectin, Mgat5 modified glycan, or polylactosamine glycan; (b) mixing the cells, lectin, and a test compound under conditions which permit the formation of a lectin-Mgat5 modified glycan lattice, complexes between the lectin and one or more glycan, and/or receptor clustering; (c) detecting a lectin-Mgat5 modified glycan lattice, complexes, lectin, Mgat5 modified glycan, polylactosamine modified glycan, or alterations to the lattice, complexes, lectin, Mgat5 modified glycan, or polylactosamine modified glycan and/or receptor clustering; and (d) comparing to a control to determine if the test compound alters the lectin-Mgat5 modified glycan lattice or a component thereof and potentially regulates receptor clustering.

### Claim 8 (depends on 4, 5, 6)

A compound identified using a method of claim 4, 5, 6, or 7.

### Claim 9

A method for regulating receptor clustering on cell surfaces comprising altering glycans on the cell surface associated with receptor clustering.

### Claim 10 (depends on 9)

A method as claimed in claim 9 wherein the receptor is a receptor that stimulates immune reactions, preferably T cell receptor, Ig receptor, B cell receptor, and NK receptor, a member of the HER family of transmembrane receptor tyrosine kinases, preferably epidermal growth factor (EGF) receptor, HER2 (neu, Erb2), HER3 (Erb3), and HER4 (Erb4)], a cadherin receptor, an interleukin (IL) receptor, TNFγ receptor, or an integrin.

### Claim 11 (depends on 9)

A method as claimed in claim 9 wherein the glycans are altered by modulating one or more glycosyltransferase enzyme involved in the synthesis of the glycans

### Claim 12 (depends on 11)

A method as claimed in claim 11 wherein the glycans are Mgat5 modified glycans and the glycosyltransferase is Mgat5.

### Claim 13 (depends on 11)

A method as claimed in claim 11 wherein the glycans are polylactosamine modified glycans and the glycosyltransferase is Mgat5.

### Claim 14

A method for regulating receptor clustering on cell surfaces, preferably T cell receptor clustering, comprising modulating Mgat5 activity, the amount of Mgat5 modified glycans, polylactosamine modified glycans, or lectin-Mgat5 modified glycan lattice, or the amount of binding or interaction of one or more components of a lectin-Mgat5 modified glycan lattice.

### Claim 15

A method for reducing receptor clustering on a cell surface by increasing the amount of Mgat5 modified glycans, polylactosamine modified glycans, or lectin-Mgat5 modified glycan lattice on the cell surface.

### Claim 16

A method for restricting T cell receptor recruitment in response to an agonist or increasing T cell activation threshold comprising increasing Mgat5 modified glycans, polylactosamine modified glycans, or galectin-Mgat5 modified glycan lattice on the surface of the cells, or enhancing the interaction between one or more components of a galectin-Mgat5 modified glycan lattice.

### Claim 17 (depends on 15, 16)

A method as claimed in claim 15 or 16 wherein the glycans or lattice are increased by increasing the amount or activity of one or more glycosyltransferase enzyme, preferably Mgat5.

### Claim 18

A method for increasing receptor clustering on a cell surface by decreasing the amount of Mgat5 modified glycans, polylactosamine modified glycans, or lectin-Mgat5 modified glycan lattice on the cell surface.

### Claim 19

A method for lowering T cell activation threshold to agonists or enhancing T cell receptor clustering comprising decreasing Mgat5 modified glycans, polylactosamine modified glycans, or galectin-Mgat5 modified glycan lattice on the surface of the T cells, or dissociating galectin from such glycans or lattice thereby lowering the T cell activation threshold.

### Claim 20 (depends on 18, 19)

A method as claimed in claim 18 or 19 wherein the glycans or lattice are decreased by decreasing the amount of or activity of a glycosyltransferase, preferably Mgat5.

### Claim 21

A method for treating or preventing a condition associated with decreased or increased receptor clustering or a receptor clustering defect in a subject comprising altering glycans associated with receptor clustering.

### Claim 22 (depends on 21)

A method as claimed in claim 21 wherein the glycans are altered by modulating a glycosyltransferase enzyme involved in the synthesis of the glycans, preferably Mgat5.

### Claim 23

A method for treating or preventing a condition associated with decreased or increased receptor clustering, or a receptor clustering defect, comprising modulating Mgat5 activity, the amount of Mgat5 modified glycans, polylactosamine modified glycans, or lectin-Mgat5 modified glycan lattice, and/or the amount of binding or interaction of one or more components of a lectin-MgatV modified glycan lattice.

### Claim 24

A method for treating or preventing an autoimmune disease in a subject comprising reducing T cell receptor clustering in the subject by increasing the amount of Mgat5 modified glycans, polylactosamine modified glycans, and/or lectin-Mgat5 modified glycan lattice on the surface of T cells of the subject.

### Claim 25

A method of, and products for, diagnosing and monitoring conditions characterized by an abonormality in receptor clustering comprising assaying for differential glycosylation of the receptor.

### Claim 26 (depends on 25)

A method as claimed in claim 25 wherein differential glycosylation is assayed by determining the presence of Mgat5 modified glycans, polylactosamine modified glycans, lectin-Mgat5 modified glycan lattice, or alterations in such glycans or lattice, compared to a control.

### Claim 27 (depends on 1, 2)

A method of, and products for, diagnosing and monitoring conditions characterized by an abnormality or defect of receptor clustering involving the interaction of a galectin and Mgat5 modified glycan or polylactosamine modified glycan comprising determining the presence of one or more complex as claimed in claim 1, a galectin-Mgat5 modified glycan lattice as claimed in claim 2, a Mgat5 modified glycan, a polylactosamine modified glycan, or one or more of an altered Mgat5 modified glycan, polylactosamine modified glycan, or a galectin-Mgat5 modified glycan lattice.
